OS Therapies Announced That The Last Patient Enrolled In AOST-2121 Clinical Trial Of OST-HER2 In Recurred, Resected Osteosarcoma Has Received Its Last Treatment Dose, Primary Endpoint Analysis Is Expected By Early In The Fourth Quarter Of 2024
Portfolio Pulse from Benzinga Newsdesk
OS Therapies has completed the treatment phase for the last patient in its AOST-2121 clinical trial of OST-HER2 for osteosarcoma. The primary endpoint analysis is expected by early Q4 2024, with topline data readout anticipated in the same quarter.
August 29, 2024 | 11:58 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
OS Therapies has completed the treatment phase for the last patient in its AOST-2121 clinical trial of OST-HER2 for osteosarcoma. The primary endpoint analysis is expected by early Q4 2024, with topline data readout anticipated in the same quarter.
The completion of the treatment phase and the upcoming data analysis are significant milestones for OS Therapies. However, the impact on the stock price is neutral in the short term as the primary endpoint analysis and topline data readout are not expected until Q4 2024.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100